Search research articles
Contact Us
Filters
Showing results (61-70 of 277) with videos related to
Page
of 28
Sort By:
The Oncologist
|
March 30, 2018
Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
Gerald Edelman, Jordi Rodon, Joanne Lager, et al.
Breast Cancer Research and Treatment
|
October 8, 2016
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
Sara M Tolaney, Hovav Nechushtan, Ilan-Gil Ron, et al.
Cell Reports
|
February 21, 2020
Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection
Mu-Yan Cai, Connor E Dunn, Wenxu Chen, et al.
Cancer Research
|
December 6, 2006
Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling
Susumu Kobayashi, Takeshi Shimamura, Stefano Monti, et al.
Plos One
|
March 13, 2014
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma
John C Morris, Antoinette R Tan, Thomas E Olencki, et al.
Frontiers in Oncology
|
January 24, 2022
Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Michael S Gordon, Geoffrey I Shapiro, John Sarantopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2005
Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer
John R Goffin, Ian C Anderson, Jeffrey G Supko, et al.
Nature Reviews. Clinical Oncology
|
February 3, 2025
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck
Jia Luo, Justin A Bishop, Steven G DuBois, et al.
Cancer Research
|
July 5, 2006
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272
Takeshi Shimamura, Hongbin Ji, Yuko Minami, et al.
Molecular Cell
|
October 27, 2020
CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress
Feng Li, David Kozono, Peter Deraska, et al.
Page
of 28
Search research articles
Search
Showing results (61-70 of 277) with videos related to
Sort By:
Page
of 28
The Oncologist
|
March 30, 2018
Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
Gerald Edelman, Jordi Rodon, Joanne Lager, et al.
Breast Cancer Research and Treatment
|
October 8, 2016
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
Sara M Tolaney, Hovav Nechushtan, Ilan-Gil Ron, et al.
Cell Reports
|
February 21, 2020
Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection
Mu-Yan Cai, Connor E Dunn, Wenxu Chen, et al.
Cancer Research
|
December 6, 2006
Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling
Susumu Kobayashi, Takeshi Shimamura, Stefano Monti, et al.
Plos One
|
March 13, 2014
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma
John C Morris, Antoinette R Tan, Thomas E Olencki, et al.
Frontiers in Oncology
|
January 24, 2022
Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Michael S Gordon, Geoffrey I Shapiro, John Sarantopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2005
Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer
John R Goffin, Ian C Anderson, Jeffrey G Supko, et al.
Nature Reviews. Clinical Oncology
|
February 3, 2025
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck
Jia Luo, Justin A Bishop, Steven G DuBois, et al.
Cancer Research
|
July 5, 2006
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272
Takeshi Shimamura, Hongbin Ji, Yuko Minami, et al.
Molecular Cell
|
October 27, 2020
CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress
Feng Li, David Kozono, Peter Deraska, et al.
Page
of 28